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11.1 Background
 Three hours of exposure to organic dust in a swine barn causes an acute inflammatory
response in both upper and lower airways of healthy subjects and an increase in bronchial
responsiveness to methacholine (Larsson et al., 1997; Larsson et al., 1994a; Larsson et al.,
1994b; Malmberg et al., 1993; Muller-Suur et al., 1997; Wang et al., 1997; Wang et al., 1996;
Wang et al., 1998; Zhiping et al., 1996). The reaction is characterized by an influx of
inflammatory cells into the airways, cell activation and cytokine/mediator release as
demonstrated in a number of studies at our laboratory (Larsson et al., 1999; Muller-Suur et al.,
2000; Palmberg et al., 1998; Wang et al., 1999). This reaction is known as Organic Dust Toxic
Syndrome (ODTS), characterized by flu-like symptoms following exposure to organic dust
(Seifert et al., 2003). The duration of symptoms is often less than 24 hours.
 In the present thesis, the acute inflammatory response following swine house dust exposure
is used as a model for studies of inflammatory mechanisms involved in innate immunity. The
inflammatory profile in chronic obstructive pulmonary disease (COPD), severe asthma, or
during asthma exacerbation shows similarities with the acute inflammatory response in healthy
subjects following exposure in a swine barn. Glucocorticoids and β2-agonists are the most
frequently used drugs to treat inflammation in bronchial asthma and COPD. The inflammatory
disease mechanisms and the precise mechanisms underlying the beneficial action of
glucocorticoids and β2-agonists in these context are still not fully understood.
 In this thesis, we have studied the effects of glucocorticoids or β2-agonists on the
inflammatory response following exposure to swine house dust both in vitro and in vivo. The
aim was to study features of the inflammatory mechanisms during the acute inflammatory
response induced by exposure in a swine barn and the mechanisms by which this innate
inflammatory reaction may be controlled by drugs known to interact with airway
inflammatory conditions.
 
1.2 Inflammatory responses induced by organic dust exposure
1.2.1 Organic dust toxic syndrome
 Organic dust toxic syndrome (ODTS), a condition following heavy organic dust exposure, is
associated with fever, cough, malaise, chest-tightness, dyspnea, headache, chills, nausea and
muscle pain (Von Essen et al., 1990). The symptoms usually disappear within 1-2 days.
ODTS is observed among farmers at work. The mechanism of this pathological condition is a
non-specific immune response but the exact mechanism of toxicity is not known (Von Essen
et al., 1990).
 This condition appears to be quite common among swine confinement workers. Workers in
swine confinement buildings are exposed to high levels of organic dust and to gases. Dust
levels ranging from 1.7 to 21 mg/m3 have been reported in swine farms with corresponding
endotoxin concentrations ranging from less than 0.1 to 1.9 µg/m3 (for review see (Larsson,
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22001)). Swine confinement workers have an increased frequency of airway symptoms such as
cough, phlegm, wheezing and shortness of breath and have higher prevalence of pulmonary
disorders, such as chronic bronchitis, than non-farmers and than other farmers (Zejda et al.,
1993) (Larsson, 2001). It has been demonstrated that also healthy pig farmers have signs of
airway inflammation (Larsson et al., 1992).
 Healthy, previously non-exposed, individuals exposed to organic dust in a swine house for
three hours develop ODTS with an intense airway inflammation and an increase in bronchial
responsiveness to methacholine. The inflammatory response is characterized by a massive influx
of inflammatory cells, into the upper and lower airways. The cell increase consists mainly of
neutrophilic granulocytes which increase about 20-fold and 70-75-fold in nasal and
bronchoalveolar lavage fluid, respectively (Larsson et al., 1997; Larsson et al., 1994b). There is
also a significant increase of alveolar macrophages, lymphocytes and eosinophils in
bronchoalveolar lavage fluid (Larsson et al., 1997) and an increase of pro-inflammatory
cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1α, IL-1β, IL-6 and IL-8 in
bronchoalveolar and nasal lavage fluid after exposure (Larsson et al., 1997; Wang et al., 1997).
Exposure also causes systemic effects such as increase in acute phase proteins (CRP,
orosomucoid and haptoglobin) and increase in serum IL-6 and TNF-α (Larsson et al., 1994b;
Wang et al., 1996).
 The exact mechanisms causing this condition and the components or combination of the
organic dust that elicit specific effects are still not clear. Swine dust consists of a complex
mixture of micro-organisms, fungal spores, hay, animal feed and animal products. Bacterial
endotoxin (lipopolysaccharids, LPS), Gram positive bacteria and their products, including
peptidoglycans, and (1-3) β-D-glucan from mould might contribute or be important in
mediating the response to organic dust (Larsson et al., 1999; Palmberg et al., 1998).
 
1.3 The innate immunity
 The innate immune system is a universal and ancient form of first line host defence against
invading microbial pathogens. Collectively, it consists of many interacting systems, including
epithelial barriers (skin and mucosal epithelium), antimicrobial peptides (for example
defensins) and circulating effector cells (neutrophils, mononuclear phagocytes and natural
killer (NK) cells). Immunology in recent year expresses renewed interest in innate immunity
because of its regulatory role on the adaptive immune response.
 
1.3.1 The inflammatory response
 Invading micro-organisms or tissue injury induce an inflammatory response which plays an
important role in health and disease. This response is rapidly initiated by the innate immune
system and does usually not require the participation of the adaptive immune system. The
response to organic dust mainly involves the innate, non-specific immunity.
 Inflammation is a general term used to describe the many diverse processes that tissues
employ in response to infections by pathogens and injuries. Classically, the cardinal signs of
the inflammatory reaction are redness, swelling, pain, heat and reduced function (Kuby, 1994).
These signs are characteristic for the initial phase of inflammation, termed the acute
inflammatory response.  
 The inflammatory response comprises a complex sequence of events. The systemic reaction
is manifested as fever, leukocytosis, increase of several cytokines, activation of
3cyclooxygenase and lipoxygenase pathways as well as clotting, complement activation, kinin-
forming cascades and acute phase protein synthesis in the liver. The local inflammatory
reaction is characterized by an initial increase in blood flow to the site of injury and enhanced
vascular permeability to plasma proteins and water, leading to oedema formation. At the site
of injury granulocytes from the peripheral blood infiltrate and accumulate. The aim is to
destroy, dilute or wall-off both the injurious agent and the injured tissue. The accumulation
and subsequent activation of leukocytes are crucial events in this reaction (Dempsey et al.,
2003; Kuby, 1994).
 The inflammatory response is critical for host defence, helping to clear infection. It often
disappears within a few days, is occasionally fatal as in septic shock or is gradually
transformed into a chronic inflammatory disease. Excessive inflammation may result in lung
injury and in different inflammatory diseases.
 
1.3.2 Cells
 The epithelium has a number of critical functions; these include a structural barrier against
exogenous pathogens, regulation of lung fluid balance, metabolism and/or mucociliary clearance
of inhaled agents, attraction and activation of inflammatory cells in response to injury and the
regulation of airway smooth muscle function via secretion of numerous mediators (Davies et
al., 1992; Knight et al., 2003). Thus, epithelial cells play an active role in initiating and
modulating airway inflammation.
 The airway macrophages have also since long been recognized as important for the first line of
defence against inhaled airborne constituents (Holian et al., 1990). Alveolar macrophages reside
predominantly within the bronchoalveolar air spaces and are easily accessible by lung lavage.
They have the ability to migrate to sites of inflammation. Alveolar macrophages possess a high
phagocytic and microbicidal potential. Upon activation, alveolar macrophages may release
reactive oxygen intermediates, nitric oxide, lysosomal enzymes, interferon, complement and a
wide variety of inflammatory cytokines, chemokines and mediators including prostaglandins and
leukotrienes (Lohmann-Matthes et al., 1994). They may also initiate or modulate the activities
of other immune cells.
 Neutrophils (polymorphonuclear leukocytes, PMNs) are the most abundant circulating
leukocytes. They are characterized by the presence of both a multi-lobed nucleus and
cytoplasmic granules. They can rapidly mobilize at the onset of an infection. Following
exposure and triggering, adhesion molecules promotes neutrophil adherence and subsequent
diapedesis and transmigration in response to chemokines and other chemotactic factors (Adams
et al., 1994; MacNee et al., 1993). The lifespan of the mature circulating neutrophil is estimated
to be around 7-10 hours before migrating into the tissue where they have a 3-days life span
(Kuby, 1994; Moulding et al., 1998). The defensive role of the neutrophil is to kill and eliminate
micro-organisms by mechanisms which include phagocytosis, the respiratory burst and the
release of cytotoxic peptides and proteins (Gompertz et al., 2000; Witko-Sarsat et al., 2000).
Neutrophils play an important role in the inflammatory process. Persistent activity of
neutrophils also contributes to tissue destruction due to production of proteases and reactive
oxygen metabolites. Through this mechanism, the protective role of these cells may turn into a
deleterious action targeting the host itself.
 Other cells such as mast cells, T-lymphocytes, endothelial cells, fibroblasts and eosinophils
(which are the characteristic inflammatory cell in bronchial asthma) may also contribute to the
inflammatory process and have important roles in inflammatory responses.
41.3.3 Cytokines and inflammatory mediators
 The cellular influx to inflammatory sites is mediated by a plethora of mediator substances
supporting and dispersing inflammation. These mediators are found in the serum or tissue
fluids, and are released by degranulating cells, secreted by inflammatory cells upon activation
or secreted by activated epithelial or endothelial cells at the site of inflammation. They serve
as muscle-active and oedema-promoting substances, chemotaxins and cellular activators and
inducers of all kinds of effector cells.
 Cytokines are multifunctional mediator molecules of low molecular mass (<50 kDa) which
are extremely biologically active at nano- to picomolar concentrations (Kuby, 1994). The most
important pro-inflammatory cytokines involved in starting and developing the inflammatory
response are TNF-α, IL-1α, IL-1β, IL-6, IL-8 and IFN-γ. These cytokines either act as
endogenous pyrogens (IL-1, IL-6, TNF-α), up-regulate the synthesis of secondary mediators
and pro-inflammatory cytokines by both macrophages and mesenchymal cells (including
fibroblasts, epithelial and endothelial cells), stimulate the production of acute phase proteins,
or attract inflammatory cells (IL-8).
 TNF-α is a multifunctional cytokine produced by many cell types, mainly
macrophages/monocytes but also by mast cells, endothelial cells and epithelial cells in
response to inflammation.  TNF-α can be rapidly up-regulated upon a stimulus, but also
rapidly degraded. TNF-α elicits a broad spectrum of cellular responses including lymphocyte
and leukocyte activation, cell proliferation and migration, fever, acute-phase response,
differentiation and apoptosis (Baud et al., 2001; Thomas, 2001).
 IL-6 is a circulating key pro-inflammatory cytokine known to be secreted from a number of
different cells including macrophages, fibroblasts, lymphocytes, epithelial and endothelial
cells. IL-6 is also a multifunctional cytokine which is an important factor in the immune and
haematopoietic system and it is the major mediator in the hepatic acute phase response  
(Heinrich et al., 1990; Kishimoto, 1989). IL-6 expression and secretion is induced by IL-1 and
TNF-α. In addition, IL-6 has several anti-inflammatory activities including suppression of the
pro-inflammatory cytokines TNF-α and IL-1 (Barton, 1997).
 Stimulated airway epithelial cells and alveolar macrophages can secrete IL-8, which is an
important mediator of airway neutrophil chemotaxis and has neutrophil activating properties
(Hebert et al., 1993). Recruited neutrophils may further amplify neutrophilic airway
inflammation via the generation of additional IL-8 (Gainet et al., 1998).
 
1.3.4 Innate immune recognition
 A basic concept for the innate immune system is to recognize and detect microbial invaders.
Pathogen-associated molecular patterns (PAMPs), unique for micro-organisms and
distinguished from the host, are detected by a range of different recognition molecules. Soluble
pattern recognition molecules include lysozyme and complement proteins (C1q, C3a and C5a)
and pattern recognition receptors include CD14 and the Toll-like receptors (TLR) (Palaniyar
et al., 2002).
 Two receptors which are likely to be activated by organic dust from a swine house are the
TLR2, TLR4 and TLR9 which are implicated in the recognition of peptidoglycan,
lipopolysaccharide (LPS) and bacterial DNA, respectively (Liu et al., 2001; Takeuchi et al.,
1999). Upon activation, they transduce signals for NF-κB activation.  
51.3.5 NF-κB
 Nuclear factor-κB (NF-κB) is a ubiquitous transcription factor that regulates the expression of
many inflammatory and immune genes. Many of these genes are induced in inflammatory and
structural cells and play an important role in the inflammatory process.
 Several related proteins have been characterized that belong to the Rel family of proteins.
NF-κB was originally identified as a heterodimer consisting of two subunits, p65 (RelA) and
p50 (NF-κB1) but a variety of other forms may also occur. p65 has potent transactivation
domains which are critical in transcriptional activation, whereas p50 is mainly a DNA-binding
subunit and a relatively poor transactivator (Siebenlist et al., 1994). NF-κB is present in an
inactive state in the cytoplasm, sequestered by the inhibitory protein (IκB), of which several
isoforms exist, the most abundant being IκB-α. Activation by extracellular signals induces
phosphorylation and ubiquitinylation of IκB-α by specific IκB kinases (IKK), leading to
rapid degradation, and thus release of NF-κB (figure 1)(Baldwin, 1996). As a result, NF-κB
translocates in to the nucleus and bind to NF-κB response elements in the promoter region of
many inflammatory and immune genes. Persistent NF-κB activation can in turn induce the
synthesis of IκB-α, which terminates the NF-κB response, explaining its transient nature
(Beg et al., 1993).
 Many different agents that activate the NF-κB signalling system are a consequence of
inflammation and infection. Many different bacteria and bacterial products (such as LPS),
viruses, cytokines (such as IL-1, TNF-α), physical stress and oxidative stress activate NF-κB
(Siebenlist et al., 1994). The activation and nuclear translocation of NF-κB have been
associated with increased transcription of a number of different genes, including those coding
for chemokines (IL-8), cytokines (IL-1, IL-2, IL-6, TNF-α and IL-12), enzymes, immune
receptors and adhesion molecules (Caamano et al., 2002). These mediators are required for the
ability of inflammatory cells to migrate into areas where NF-κB is being activated. Thus, NF-
κB is an important component of the innate immune response to invading micro-organisms.
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 Figure 1. Activation of the transcription factor NF-κB (Barnes et al., 1997). Reprinted from
Barnes PJ and Karin, M N Engl J Med, 336(15), 1066-71. Nuclear factor-kappaB: a pivotal
transcription factor in chronic inflammatory diseases. Copyright © 1997, with permission from
Massachusetts Medical Society. All rights reserved.
 
1.4 Bronchial responsiveness
 Airway or bronchial responsiveness describes the tendency of the airway to constrict to
stimuli, such as spasmogenic chemical mediators or physical stimuli (O'Byrne et al., 2000).
Bronchial responsiveness is measured as the change in airway calibre after inhalation of a
bronchoconstrictor agent. A variety of different stimuli are being used to measure bronchial
responsiveness, including “direct” and “indirect” stimuli. Direct stimuli act direct on airway
smooth muscle receptors and include methacholine, histamine, cysteinyl leukotrienes and
prostaglandin D2. Indirect stimuli act on inflammatory cells, epithelial cells and nerves and
include exercise, inhaled hyper- and hypotonic saline, cold/dry air and adenosine (Joos et al.,
2003).
 Airway hyperresponsiveness is one of the cardinal features of asthma. Inhalation of ozone
induces hyperresponsiveness to methacholine in healthy subjects and an increased
neutrophilic influx into the airways (Seltzer et al., 1986). Viral respiratory infections induce
airway hyperresponsiveness in asthmatic and healthy subjects (Busse, 1994). Thus, bronchial
hyperresponsiveness and airway inflammation seem to be related. However, it is not clear
whether the inflammatory reaction causes bronchial hyperresponsiveness or if these two
findings are parallel phenomena.
7 A number of different mechanisms likely interact to cause airway hyperresponsiveness and
probably differ in normal and asthmatic subjects (Lotvall et al., 1998; O'Byrne & Inman,
2000). The mechanisms responsible for hyperresponsiveness are unknown but may involve
airway epithelial damage, thickening of basement membrane and airway wall, release of
mediators with the capacity to cause bronchial smooth muscle contraction, oedema and
exudation of plasma.
 
1.5 Pharmacological intervention
 Acute inflammation is a natural response for the organism to defend itself from harmful micro-
organisms and other toxic agents. Sometimes in certain diseases this response turns towards
the own body and preventing excessive injury can be important in protecting the organism. At
that point glucocorticoids or other anti-inflammatory agents can be useful in the treatment of
the disease. However, it is important to emphasize that inflammation is a natural defending
process and that there is a balance between protection and injury.
 
1.5.1 Glucocorticoids
Glucocorticoids are widely used as an anti-inflammatory agent and are currently the most
effective anti-asthma therapy (Barnes, 1998). The anti-inflammatory action of glucocorticoids
is mediated by a glucocorticoid receptor which is localized in the cytoplasm in most cell
types. Steroids are lipophilic and cross the cell membrane rapidly and enter the cytoplasm
where it binds to the glucocorticoid receptor. The inactive glucocorticoid receptor is bound to
a protein complex  that includes two molecules of heat shock protein 90 (hsp90) and once the
glucocorticoid binds to the receptor, the heat shock proteins dissociate which activates the
glucocorticoid-receptor complex allowing it to rapidly translocate into the nucleus (Brattsand
et al., 1994). The glucocorticoid-receptor complex binds to specific DNA sequences of the
glucocorticoid response elements (GREs), and regulates the transcription of target genes which
can either be repressed (inflammatory genes) or induced (anti-inflammatory genes; table 1)
(Schleimer, 1993). The glucocorticoid receptor can also interact with activated transcription
factors such as nuclear factor-κB (NF-κB) or activator protein-1 (AP-1) to inhibit the
expression of multiple inflammatory genes (Adcock, 2001). Post-transcriptional mechanisms
have also been suggested to contribute to the action of glucocorticoids, such as destabilize or
stabilize specific mRNAs (Umland et al., 2002).
8Table 1. Glucocorticoid regulated genes (Adcock et al., 2003).
Increased transcription
Lipoprotein-1/annexin-1 (phospholipase A2 inhibitor)β2-adrenoceptor
Secretory leukocyte inhibitory protein (SLPI)
Clara cell protein (CC10, phospholipase A2 inhibitor)
IL-1 receptor antagonist
IL-1R2 (decoy receptor)
IκBα (inhibitor of NF-αB)
MKP-1 (MAPK phosphatase)
CD163 (scavenger receptor)
Decreased transcription
Cytokines (IL-1, 2, 3, 4, 5, 6, 9, 11, 12, 13, 16, 17, 18, TNFα, GM-CSF, SCF)
Chemokines (IL-8, RANTES, MIP-1α, MCP-1, MCP-3, MCP-4, eotaxin)
Inducible nitric oxide synthase (iNOS)
Inducible cyclo-oxygenase (COX-2)
Endothelin-1
NK1 receptors, NK2 receptors
Adhesion molecules (ICAM-1, E-selectin)
Cytoplasmic phospholipase A2 (cPLA2)
CD163, cluster differentiation 163; GM-CSF, granulocyte macrophage-cell stimulating factor; SCF, stem cell
factor; RANTES, Regulated upon activation normal T-cell expressed and secreted; MIPIα, macrophage
inflammatory protein-1α; MCP, monocyte chemoattractant protein; NK, neurokinin; ICAM-I, intercellular
adhesion molecule I.
Thus, glucocorticoids inhibit the expression of several key proteins including pro-
inflammatory cytokines involved in the control of inflammation.  Glucocorticoids may have
direct inhibitory effects on many of the cells involved in airway inflammation, including
macrophages, T-lymphocytes, eosinophils and airway epithelial cells. Inhaled glucocorticoids
decrease the number and activation status of most inflammatory cells in the bronchus,
including mast cells, eosinophils, T-lymphocytes and dendritic cells. In addition to their
suppressive effects on inflammatory cells, glucocorticoids may also inhibit plasma exudation
and mucus secretion in inflamed airways (Barnes, 1998; van der Velden, 1998).
Inhaled glucocorticoid therapy is the most effective therapy for patients with asthma with
significant effects on symptoms, exacerbations lung function and bronchial
hyperresponsiveness (Barnes, 1995b). Glucocorticoids have, however, no effect on the
progression of COPD. Although glucocorticoids have been used for a long period of time, the
precise mechanism of action is still not completely understood.
1.5.2 β2-Agonists
 Inhaled selective ß2-agonists are the most widely
 used treatment for the acute relief of asthma
symptoms. In patients with asthma, β-adrenoceptor agonists cause bronchodilation and
reduced responsiveness to a number of bronchoconstrictor stimuli (bronchoprotection). The
major action of β-adrenoceptor agonists in asthma is the functional antagonism on airway
smooth muscles leading to relaxation.
 The ß2-agonists bind to the ß2-adrenoceptor, causing activation of the receptor and
subsequent stimulation of adenylyl cyclase with the formation of cyclic adenosine
monophosphate (cAMP). CyclicAMP acts as a second messenger and relaxes the bronchial
smooth muscle in part by protein kinase A -activation (Barnes, 1995a; Johnson, 1998).
9 Long-term use of ß2-agonists is associated with tolerance to the bronchoprotective effect
due to desensitization of the ß2-adrenoceptor. Reduced responsiveness of receptors as a
consequence of chronic stimulation by an agonist is a general biological phenomenon and β2-
adrenoceptors are no exception. Stimulation of the β2-adrenoceptor leads to homologous
desensitization via three steps; uncoupling from the stimulatory G protein, sequestration
(internalisation) into the cell and destabilization of the β2-adrenoceptors mRNA (Lohse, 1993;
Nijkamp et al., 1992).
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 The general aim of the thesis was
• to study how glucocorticoids or β2-agonists interfere with the acute non-aquired
inflammatory response exemplified by swine house dust exposure in vitro and in vivo.
 
 Specific aims were:
• to study the in vitro effect and time-kinetics of two different glucocorticoids,
fluticasone propionate or budesonide, on the swine house dust- or LPS- mediated
release of pro-inflammatory cytokines from epithelial cells and alveolar macrophages,
respectively.
 
• to investigate whether the transcription factor NF-κB is involved in the signal
transduction of swine house dust-mediated cytokine release from epithelial cells.
• to study the effect of glucocorticoids on the activation of NF-κB.
 
• to study the effect of inhaled and intra-nasally administered fluticasone, on the airway
inflammatory response and bronchial responsiveness to methacholine in healthy
subjects following exposure to organic dust in a swine barn.
• to study the effect of exposure and medication with fluticasone or salmeterol on the
capability of alveolar macrophages to release cytokines ex vivo.
• to study the effect of a long-acting β2-agonist, salmeterol (regular treatment or single
dose) on the increased bronchial responsiveness to methacholine in healthy subjects
following exposure in a swine barn.
• to study whether salmeterol influences the inflammatory response induced by
exposure in a swine barn in healthy subjects.
 
2 Aims of the Thesis
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 The methods are briefly summarised below and detailed descriptions of methods are provided
in paper I-V.
 
3.1 In vitro studies
3.1.1 Cells
 (Study I, II and IV)
 For in vitro studies the human pulmonary epithelial carcinoma cell line A549 (American Type
Culture Collection, Rockville, Maryland, USA) was used (study I and II). Alveolar
macrophages were obtained by bronchoalveolar lavage of healthy subjects and the cells were
cultured both for in vitro studies and ex vivo studies (study I and IV).
 
3.1.2 Swine dust extract
 (Study I and II)
 Swine dust was collected in a swine house, on surfaces located approximately 1.2 m above the
floor. The dust was dissolved in culture medium supplemented with penicillin and
streptomycin. A stock solution was prepared which was thoroughly mixed and put in an
ultrasound bath for 10 minutes.
 
3.1.3 Measuring effect of glucocorticoids
 (Study I)
 Epithelial cells were stimulated with swine house dust (100 µg/ml) for 24 hours and alveolar
macrophages were stimulated with LPS (100 µg/ml) for 8 hours. Budesonide or fluticasone
propionate (10-13 to 10-6 M) were co-incubated with swine dust or LPS and added before or
after the stimuli at different time points. Cell supernatants were frozen until analysed for
cytokine content (IL-6, IL-8 and TNF-α).
 
3.1.4 Measurements of NF-κB activity
 (Study II)
 Epithelial cells were transfected with reporter plasmids from the human IL-6 promoter
(containing NF-κB binding site)  or  reporter plasmids containing 3 copies of the NF-κB
binding site (3xNF-κB enhancer region), fused to the luciferase (LUC) reporter gene. For
control experiments, respective reporter plasmid with mutated NF-κB binding sites, fused to
the luciferase (LUC) reporter gene, were used. Transfection was performed by incubating the
cells with Lipofectamine and reporter plasmids for 3 hours in serum-free medium. Then fresh
culture medium was added to the wells, resulting in a final concentration of  10% FCS, to
incubate for another 20 hours until the experiment was performed. Experiments using co-
transfection with CMV-IκBα expression vector (0, 5 or 20 ng) were also performed.  
3 Materials and Methods
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 The transfected cells were stimulated for 24 hours with swine house dust (100, 200 or 400
µg/ml) or TNF-α (200 U/ml) and in some experiments co-incubated with
pyrrolidinedithiocarbamate (PDTC; 100 µM), fluticasone propionate (10-11 to 10-8 M) or
dexamethasone (10-6 M). The cells were harvested and luciferase assay performed with the
GeneGlow kit (Bio-Orbit, Turku, Finland). By measuring enzymatic activity of the luciferase
protein, the activity of the reporter plasmid was revealed. For some experiments, the
supernatants were collected and frozen until IL-6 and IL-8 concentrations were measured. In
addition, NF-κB or C/EBPβ DNA binding in nuclear extracts from swine dust-stimulated (0 or
200 µg/ml, 30 minutes) epithelial cells was measured using the electromobility shift assay.
 
3.1.5 Main questions
 Study I.
 The dose-response effect and time-kinetics of fluticasone propionate and budesonide on the
cytokine response from swine dust-stimulated epithelial cells and from LPS-stimulated
alveolar macrophages were evaluated.
 
 Study II.
 The main aim was to evaluate whether NF-κB is involved in the signal transduction of swine
dust-mediated IL-6 and IL-8 release from epithelial cells. The swine dust-induced reporter
gene activities of the IL-6 promoter and the 3x NF-κB enhancer region, in parallel with the IL-
6 and IL-8 release, were investigated. Furthermore, these parameters were also measured when
inhibiting NF-κB activation, through addition of the chemical NF-κB blocking agent PDTC or
through increased expression of IκBα or through mutating the NF-κB binding sites.
Additionally, swine dust-induced NF-κB and C/EBPβ DNA binding was evaluated. Another
aim was to investigate whether glucocorticoids influenced the dust-mediated activation of NF-
κB and cytokine response.
 
3.2 Human studies in vivo and ex vivo
3.2.1 Subjects
The studies were approved by the local ethics committees and all subjects gave their informed
consent to participate in the studies. Three separate trials were performed involving healthy
subjects (table 2).
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Table 2. Description of the trials and the participating subjects.
Trial No. of
subjects
(men)
Mean
age
(range)
Exposure# Type of study Groups Results
in Study
1 24
(19)
27
(21-47)
600-900
pigs
Randomized,
single-blind
2 weeks of treatment
Placebo (n=8)
Fluticasone (n=8)1
Salmeterol (n=8)2
III, IV, V
2 12
(5)
24
(18-32)
300 pigs Randomized,
single-blind
One single dose
Placebo (n=6)
Salmeterol (n=6)3
V
3 8
(2)
37
(24-52)
no Randomized,
single-blind,
cross-over
One single dose
Placebo or salmeterol4
V
# Exposure to organic dust involves a three hours stay in a swine confinement building.
1Two weeks treatment with fluticasone 500 µg b.i.d. for inhalation and 100 µg once daily
intranasally.
2 Salmeterol inhalation 50 µg b.i.d. for two weeks.
3One single dose salmeterol (100 µg) inhaled one hour before the start of the exposure.
4 One single dose salmeterol (100 µg) inhaled 2 or 8 hours before methacholine provocation.
3.2.2 Designs and main questions
 Study III.
 The effect of 2 weeks treatment with fluticasone propionate (500 µg b.i.d. for inhalation and
100 µg once daily intra-nasally) on the increased bronchial responsiveness to methacholine,
the systemic response, the upper airway inflammatory response and symptoms, induced in
healthy subjects following exposure to organic dust, was evaluated.  Nasal lavage and serum
samples were obtained before and after treatment and exposure in a swine house. Lung
function tests and bronchial methacholine provocation were performed before the 2 weeks
treatment period and 7 hours after the start of the exposure (approximately 8 hours after the
last dosing).
 
 Study IV.
 The effect of 2 weeks inhalation of fluticasone propionate (500 µg b.i.d.  for inhalation),
salmeterol (50 µg b.i.d.) or placebo on the increase in cellular and cytokine concentration in the
lower airways following exposure was evaluated. Additionally, we investigated the effect of
exposure of healthy individuals to organic dust in a swine barn, on the capability of alveolar
macrophages to release cytokines ex vivo. Bronchoalveolar lavage was performed before the 2
week treatment period with inhaled placebo, fluticasone or salmeterol and 24 hours after
exposure in the swine house. The influence of treatment on the alveolar macrophage function
was also evaluated.
 
 Study V.
 We investigated the effect of salmeterol, after two weeks treatment (50 µg b.i.d.) and after one
single dose (100 µg) on the increased bronchial responsiveness to methacholine induced in
healthy subjects exposed in a swine barn. A control study was performed to find out whether
a single dose inhaled salmeterol (100 µg) attenuated the bronchial response to methacholine in
healthy unexposed subjects. Lung function measurements and a bronchial methacholine
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provocation were performed before medication (approximately 2-3 weeks before exposure)
and 7 hours after the start of the exposure (approximately 8 hours after last dosing).
 
3.3 Methods
 Methods are briefly summarized below, for details see individual manuscripts.
 
3.3.1 Nasal lavage
 (Study III)
 Nasal lavage (NAL) was performed before the start of medication, after 2 weeks of treatment
(1 hour before exposure) and 7 hours after the start of the exposure. A nasal lavage method
procedure described by Bascom and Pipkorn (Bascom et al., 1988; Pipkorn et al., 1988) was
used with minor modifications (see study IV). In each nostril 5 ml 0.9% NaCl was instilled
and withheld for 10 seconds and then expelled and collected. The volume was measured, the
cells were counted and the fluid was frozen for later analyses.
 
3.3.2 Bronchoalveolar lavage
 (Study I and IV)
 Bronchoscopy was performed with a flexible fibreoptic bronchoscope under local anaesthesia.
A total of 250 ml sterile saline solution was used. The lavage fluid was collected, volume
measured, cells counted, cell viability determined and fluid frozen for later analyses. Before in
vitro experiments, cells were added onto culture plates and allowed to adhere for 2 hours at
370C, in culture medium containing 5% fetal calf serum and in the presence of 5% CO2. The
non-adherent cells were then removed by washing with serum-free medium.
 
3.3.3 Peripheral blood and symptoms
 (Study III and V)
 Blood samples were allowed to coagulate at room temperature for 1 hour before centrifugation
(1550 g for 10 min). Following exposure in swine houses, symptoms (shivering, headache,
malaise, muscle pain and nausea) were assessed using a questionnaire. The symptoms were
graded according to a severity scale (1= no symptoms, 5= severe symptoms). Only 4 or 5
were classified as clinically relevant. Oral temperature was measured with an electronic mouth
thermometer (Teflo, Sweden).
 
3.3.4 Analyses of inflammatory mediators
 (Study I, II, III, IV and V)
 The cell culture supernatants, nasal lavage fluid, bronchoalveolar lavage fluid and serum were
dispensed in several aliquots, kept at -70°C and underwent only one freeze-thaw cycle before
assay. IL-6, IL-8, TNF-α, albumin, α2-macroglobulin, GM-CSF and RANTES were all
quantified by different enzyme-linked immunosorbent assays (ELISA) either using commercial
high sensitive sandwich enzyme immunoassay kits (QuantikineTM R&D Systems, Europe
Ltd, UK) or commercially available antibody pairs, standards and controls (R&D Systems
Europe, Abingdon, UK) together with an enzyme amplified detection system when necessary
(see each article). Analysis of LTE4 (Study IV) was performed with an enzyme immunoassay
15
(EIA) procedure. For all analyses, duplicates were measured and an intra-assay coefficient of
variation of <10% and an inter-assay coefficient of variation <20% was accepted. Absorbance
was read using a Thermomax 250 reader (Molecular Devices, Sunnyvale, CA, USA).
 
3.3.5 Lung function and bronchial responsiveness
 (Study III and V)
 Lung function (FEV1 and VC) was measured using a wedge spirometer (Vitalograph®, Medical
Instrumentation, Buckingham, U.K.) according to the recommendations of the American
Thoracic Society (1995). Local reference values were used (Hedenstrom et al., 1985;
Hedenstrom et al., 1986). A mini-Wright peak flow meter (Clement Clarke Ltd, London, UK)
was used to measure peak expiratory flow (PEF).
 Bronchial responsiveness was assessed by a methacholine challenge, described in detail
previously (Malmberg et al., 1991). Inhalation of the diluent was followed by inhalation of
doubling concentrations of methacholine, starting at 0.5 mg/ml up to 32 mg/ml or to 64 mg/ml
or until FEV1 decreased by 20%. The results were expressed as the concentration or
cumulative dose causing a 20% decrease in FEV1 (PC20FEV1 and PD20FEV1, respectively) and
as the dose-response slope (percent FEV1-decrease as a function of the cumulated dose of
methacholine calculated with linear regression (Chinn, 1998; Chinn et al., 1993))
 
3.3.6 Exposure and dust measurements
 (Study III, IV and V)
 Exposure to organic dust involves a three hours stay in a swine confinement building during
which pigs are weighed, a procedure leading to dust agitation. At each occasion, the individuals
carried equipment to sample inhalable (<10 µm) and respirable (<5 µm) dust. Inhalable dust
(IOM inhalable dust sampler, SKC Ltd, Blandford, England) and respirable dust (plastic
cyclone samplers, Casella London Limited, Bedford MK42 7JY, England) were sampled,
weighed and analyzed for endotoxin (Limulus amebocyte assay, QCL-1000, Endotoxin,
BioWhittaker, Walkersville, USA).
 
3.3.7 Statistics
 Results are presented as mean and SEM or as median (25th-75th percentile). For comparisons
both parametric and non-parametric tests were used. Corrections for multiple comparisons
have been performed when appropriate. Statistical calculations are described in detail in each
paper.
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4.1 Effects of glucocorticoids on organic dust-induced responses
4.1.1 Glucocorticoids: cytokine release in vitro
 (Study I)
 In swine-dust stimulated epithelial cells and in LPS-stimulated alveolar macrophages,
simultaneous incubation of the stimulus and fluticasone or budesonide inhibited the increase in
IL-6 and IL-8 release from epithelial cells and IL-6, IL-8 and TNF-α release from alveolar
macrophages in a dose-dependent manner (fig. 2). At the highest concentration (10-9-10-8M),
fluticasone inhibited the swine dust (or LPS)-induced release of these cytokines by at least
75%, with the exception of IL-8 release from alveolar macrophages that was inhibited by 33%.
 Fluticasone was about 10 times more potent than budesonide in inhibiting cytokine release
from epithelial cells and alveolar macrophages. This might be explained by the fact that
fluticasone is about 300-fold more lipophilic than budesonide and has higher affinity for the
glucocorticoid receptor (Johnson, 1995).
 We also showed that it is important to consider the stimulating effect of the diluent in
which the drugs are solved, in addition to the stimuli itself. We dissolved the drugs in 99.5%
ethanol or dimethylacetamid. High concentrations of these diluents (0.05% ethanol
corresponding to a budesonide concentration of 10-5M and 0.0001 % dimethylacetamid
corresponding to a fluticasone concentration of 10-8M) in combination with either swine house
dust or LPS, enhanced the IL-6 and IL-8 release significantly from A549 epithelial cells and
alveolar macrophages. The diluents, at these concentrations, did not significantly enhance the
IL-6, IL-8 or TNF-α response to LPS in human alveolar macrophages but may do that at
higher concentrations.
 Jusko studied the pharmacokinetics and receptor-mediated pharmacodynamics of
glucocorticoids and concluded that the slow onset of biological responses to glucocorticoids is
not caused by pharmacokinetic factors, but by the time needed for cell movement, mediator
suppression or mRNA and protein synthesis (Jusko, 1990; Jusko, 1995). We found that the
glucocorticoid-induced inhibition of cytokines from both lung epithelial cells and alveolar
macrophages was not enhanced by pre-incubation of the glucocorticoid for different periods of
times before adding either swine house dust or LPS. Furthermore, adding the glucocorticoids
after the stimuli still resulted in a significant inhibitory effect. Conclusions from our time-
kinetic results are that the suppression of cytokine release from these cells by glucocorticoid
starts rapidly and might thus be a direct non-gene-mediated effect.
 
4 Results and Discussion
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 Figure 2. Results from Study I. Effect of fluticasone propionate incubation, in combination with
swine house dust (100 µg/ml; 24 hours) or LPS (100 µg/ml; 8 hours), on the release of IL-6 and
IL-8 from A549 epithelial cells or on the release of IL-6, IL-8 and TNF-α from human alveolar
macrophages respectively. Results are presented as percent of cytokine release induced by swine
house dust or LPS only (mean ± SEM). *:p<0.05; **:p<0.01; ***:0<0.001 versus swine dust or
LPS respectively.
 
4.1.2 NF-κB activation in vitro
 (Study II)
 We have used several different approaches to show that NF-κB was activated in lung
epithelial cells after swine house dust stimulation and that NF-κB is involved in the dust-
mediated IL-6 and IL-8 release. Swine dust increases reporter gene activities of the IL-6
promoter and the 3x NF-κB enhancer region, in parallel with IL-6 and IL-8 release, and an
intact NF-κB binding site was required. By adding the NF-κB blocking agent PDTC or by
increasing expression of IκBα, inhibition of reporter gene activities of the IL-6 promoter and
the 3x NF-κB enhancer region was demonstrated. Additionally, swine dust induced NF-κB
DNA binding, composed of the NFκB1 and RelA proteins, and induced a small increase of
C/EBPβ DNA binding.
 
4.1.3 Glucocorticoids: NF-κB activation in vitro
 (Study II)
 Fluticasone, in a dose-dependent manner, and dexamethasone, at one tested dose, inhibited the
swine house dust-induced activation of the reporter gene containing 3x the NF-κB enhancer
region.
 We also confirmed previous results that fluticasone inhibited IL-6 and IL-8 from epithelial
cells in a dose-dependent manner. The conditions for these two studies were slightly different.
In Study I, the culture medium contained no FCS and the cells were not pre-transfected while
in study II, the culture medium contained 10% FCS and the cells were pre-transfected. In both
studies we showed that swine house dust-induced IL-6 and IL-8 release from epithelial cells
are inhibited to almost basal, pre-exposure levels, by fluticasone at 10-9M. Thus, transfected
and non-transfected cells behaved similar in respect of cytokine inhibition.
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 In parallel with the inhibition of cytokine release by fluticasone (10-9 M), the NF-κB
reporter gene activity was significantly inhibited, but not to basal levels. We also found that
incubation with the NF-κB blocking agent PDTC together with swine house dust inhibited the
reporter gene activities of the 3x NF-κB enhancer region and of the dust-induced IL-6 and IL-8
release to basal levels. Increasing the levels of IκBα, inhibited the swine house dust-induced
IL-6 promoter reporter gene activity. These results taken together demonstrated that
inhibition of IL-6 and IL-8 from epithelial cells by fluticasone is, in part, explained by
inhibition of NF-κB activation.
 Both the IL-6 and the IL-8 genes contain transcriptional control element motifs for NF-κB,
AP-1 in the promoter region (Kishimoto, 1989; Roebuck, 1999). Many anti-inflammatory
effects of glucocorticoids have been linked to their ability to inhibit the activation of NF-κB
(McKay et al., 1999). Several mechanisms have been described for the antagonistic effect of
glucocorticoids on NF-κB. Through protein-protein interaction, the activated glucocorticoid
receptor can repress NF-κB activation and/or function. This interaction can occur either by
blocking the access of NF-κB to its DNA site or by forming a complex with NF-κB (either in
the cytoplasm or in the nucleus) which loses DNA capacity and thus preventing NF-κB-
modulated transcription. In addition, the activated receptor may indirectly inhibit the function
of NF-κB by inducing the synthesis of the NF-κB inhibitor, IκB (Barnes & Karin, 1997). In
addition, the activated glucocorticoid receptor may compete with NF-κB for nuclear co-
activators, thereby reducing and inhibiting activation by NF-κB (Almawi et al., 2002). Direct
interaction between the activated glucocorticoid receptor and NF-κB seems to be important in
repression of NF-κB activity by glucocorticoids in A549 cells (Wissink et al., 1998).
 Newton et al showed that 50-100% depression of inflammatory genes in A549 cells by
dexamethasone did not induce repression via changes of NF-κB expression (Newton et al.,
1998). Thus, inhibition of NF-κB-dependent transcription might not itself account for the full
suppressive effect of glucocorticoids in A549 cells. It is not clear how to interpret that swine
dust-induced IL-6 and IL-8 release was inhibited to basal levels while the NF-κB activity was
not. The glucocorticoid-mediated inhibition of the swine dust-induced IL-6 and IL-8 release
might, in addition to repression of NF-κB activity, also involve interaction with other
transcription factors such as AP-1 (Barnes et al., 1998). It could also interact with proteins
involved in other signalling pathways (Wikstrom, 2003), post-transcriptional mechanisms
(such as modulation of mRNA stability (Chang et al., 2001)) or the direct binding of the
glucocorticoid receptor to DNA in the promoter region of the gene resulting in repression (Ray
et al., 1990).
 
4.1.4 Glucocorticoids: nasal effects
 (Study III)
 Compared to placebo, intra-nasally administered fluticasone almost totally inhibited the
plasma protein leakage, assessed as albumin (67 kDa) and α2-macroglobulin (725 kDa)
concentrations in nasal lavage fluid (P=0.02 and P=0.06 respectively), and attenuated the nasal
IL-8, TNF-α and LTE4 response to organic dust (P=0.02, P=0.03 and P=0.07 respectively).
However, there were no significant differences between the placebo and fluticasone group
regarding the increased cell content in nasal lavage (P=0.3).
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 At present it is not clear whether glucocorticoids inhibit microvascular leakage via a direct
effect on endothelial cells or via a reduction of inflammatory mediators that increase vascular
leakage (Persson et al., 1993). We found a relationship between post-exposure increases in
albumin and α2-macroglobulin (Rho =0.79, P=0.003), albumin and IL-8 (Rho=0.90,
P=0.0007), albumin and TNF-α (Rho=0.84, P=0.004) and between albumin and LTE4 (Rho
=0.92, P=0.004). Both IL-8 and LTE4 may induce plasma exudation (Rampart et al., 1989;
Woodward et al., 1983). It is thus possible that the IL-8 and LTE4 released after exposure
contributed to the increased plasma exudation into the nasal cavity and that the inhibition by
fluticasone of the induced IL-8 and LTE4 release into the nose might have contributed to the
inhibition of plasma leakage.
 
4.1.5 Glucocorticoids: symptoms and systemic effects
 (Study III)
 Five out of eight participants in the placebo group and two out of seven participants in the
fluticasone group experienced symptoms (grade 4-5) following exposure.
 The increased serum IL-6 and oral temperature following exposure in the swine barn, was
significantly lower in the subjects treated with fluticasone compared to placebo (figure 3). It is
well known that IL-6 is an endogenous circulating pyrogen, responsible for induction of fever
during infection and inflammation. In a previous study the body temperature of 38 subjects, at
7 hours after the start of exposure in a swine barn, correlated significantly with maximal serum
IL-6 levels after exposure (Wang, 1997). Our in vitro data are in agreement with the finding of
lower IL-6 levels following exposure in the subjects who were treated with glucocorticoids.
The inhibition of IL-6 production by fluticasone might therefore have contributed to the
attenuated increase in post-exposure body temperature in the fluticasone treated group.
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 Figure 3. IL-6 concentrations in serum and oral temperature in healthy subjects before and after
exposure in a swine house. Subjects were treated with placebo (n=8) or fluticasone (n=7) for 2
weeks prior to exposure. Mean ± SEM. * P<0.05, ** P<0.01 and *** P<0.001 compared with
pre-exposure values. The increase in IL-6 and body temperature differed significantly between the
fluticasone group and the placebo group (ANOVA F=3.2; P=0.03 and F=3.5; P=0.007
respectively).
 
4.1.6 Glucocorticoids: inflammatory airway effects
Compared to placebo, there were no effects of fluticasone treatment on the organic dust-
induced increase in cell content and cytokine responses in bronchoalveolar lavage compared to
placebo (study IV). Neither was there an effect on the slight decrease in lung function or the
increased bronchial responsiveness to methacholine following exposure (study III).
In bronchoalveolar lavage fluid from placebo treated subjects, there was a significant
increase in total cell count, IL-6, TNF-α, albumin and α2-macroglobulin concentrations 24
hours after exposure in the swine barn (table 3). RANTES and GM-CSF concentrations did
not significantly increase after exposure and were 7.2 (5.9-8.4) pg/ml and <1.0 (<1.0-3.2)
pg/ml, respectively, before exposure and 9.4 (4.2-11.2) pg/ml and 2.4 (1.6-6.7) pg/ml,
respectively, after exposure in the placebo group. Fluticasone treatment did not significantly
influence any of these inflammatory mediators (table 3).
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Table 3. Findings in bronchoalveolar lavage fluid from healthy subjects before 2 weeks treatment
with inhaled placebo (b.i.d.; n=8), fluticasone (500 µg b.i.d; n=7.) or salmeterol (50 µg b.i.d.;
n=8) and 24 hours after the start of the exposure to organic dust in a swine barn. Last dosing was
one hour prior to exposure (part of study IV).
Placebo
Before After
Salmeterol
Before After
Fluticasone
Before After
Total cells
(x103/ml)
109
(73-167)
424*
(290-726)
117
(92-132)
343*
(304-437)
131
(89-147)
274*
(259-339)
IL-8
(pg/ml)
<25
(<25-57)
122
(86-174)
<25
(<25-39)
121
(67-196)
<25
(<25-<25)
262
(193-436)
IL-6
(pg/ml)
1.7
(1.3-2.0)
41.5*
(25.1-95.7)
1.6
(1.1-2.1)
37.0*
(20.9-60.3)
2.6
(1.5-3.0)
30.7*
(28.2-40.0)
TNF-α
(pg/ml)
<0.5
(<0.5-<0.5)
4.3*
(3.1-7.6)
<0.5
(<0.5-<0.5)
4.5*
(1.8-6.5)
<0.5
(<0.5-<0.5)
5.0 *
(2.5-7.1)
Albumin
(µg/ml)
52
(47-83)
112*
(95-137)
42
(38-52)
80*
(66-100)
59
(40-81)
101*
(57-131)
α2-Macro-globulin
(µg/ml)
0.16 
(0.13-0.24)
0.75*
(0.53-2.47)
0.12 
(0.07-0.29)
0.68*
(0.54-0.79)
0.22
(0.01-0.45)
0.94
(0.40-1.49)
* P<0.05 compared with pre-exposure values. There were no significant differences between the
groups. Median (25th-75th percentiles).
We found no effect of fluticasone treatment on the increase in methacholine-induced airway
responsiveness induced by exposure in a swine barn in healthy subjects. Bronchial
responsiveness to methacholine increased significantly by 3.2 (2.8-4.1) doubling concentration
steps in the placebo group and by 2.5 (1.5-3.9) doubling concentration steps in the fluticasone
group (P=0.4 between the groups) after exposure. In a meta-analysis by Currie et al. (Currie et
al., 2003), glucocorticoid inhalation reduced methacholine-induced bronchoconstriction
compared to placebo by 1.25 (95% CI 1.08 to 1.42) doubling dose/dilution shift at
low/medium dose and 2.16 (95% CI 1.88 to 2.44) doubling dose/dilution shift at high-dose in
asthmatic patients. However, the factors that predict improvement in bronchial
hyperresponsiveness by inhaled glucocorticoids are still largely unknown and the relationship
between inflammation and bronchial hyperresponsiveness is not clear. Inhalation of ozone in
normal subjects causes a neutrophilic inflammatory response in the airways and an increased
responsiveness to methacholine. Nightingale et al showed, in agreement with our findings, that
budesonide inhalation neither affected sputum neutrophils nor the increased methacholine
reactivity in normal subjects (Nightingale et al., 2000).
4.1.7 Glucocorticoids: alveolar macrophages ex vivo
 (Study IV)
 We found that exposure of healthy individuals to organic dust in a swine barn reduced the
basal release of IL-6, IL-8 and TNF-α in alveolar macrophages ex vivo (figure 4). Pre-exposure
treatment with either salmeterol or fluticasone in vivo did not influence this capability. There
was a weak tendency of fluticasone to counteract the reduced alveolar macrophage basal
function; however, with no significant differences between the groups (Figure 4). There were
no significant differences between cytokine releases in LPS-stimulated alveolar macrophages ex
vivo before compared to after exposure. There might be a reduced capability of the alveolar
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macrophages to release TNF-α following LPS stimulation after exposure in a swine barn
(placebo P=0.09). The clinical relevance of the reduced alveolar macrophage function is not
clear.
 
 
 
 Figure 4. Results from study IV. Cytokine release from un-stimulated (24 hours in culture
medium) or LPS-stimulated (100 µg/ml for 24 hours) alveolar macrophages in vitro obtained from
healthy subjects before a 2 week treatment period with either inhaled placebo (n=8) or fluticasone
(n=7; one subject had an airway infection at the time of exposure and was therefore excluded) and
24 hours after exposure in a swine house. The cells from each subject were cultured in duplicates
and the mean value of the two measurements was used for statistical calculations. Results are
presented as median and 25th to 75th percentiles. *P<0.05 compared to pre-exposure (Wilcoxon
Signed Rank test). There were no significant differences between the groups (Mann-Whitney U-
test).
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4.2 Effects of β2-agonists on organic dust-induced responses
 Salmeterol is a highly lipophilic, partial long-acting ß2-agonist providing bronchodilation for at
least 12 hours (Johnson, 1998; Johnson et al., 1993; Lotvall et al., 1993).
 
4.2.1 β2-Agonists: inflammatory responses
(Study IV and unpublished results)
We found no significant effects of inhaled salmeterol (50 µg b.i.d.) on the inflammatory
response to organic dust in either serum or bronchoalveolar lavage fluid (performed 24 hours
after exposure). Serum IL-6 concentrations increased to a maximum of 10.7 (3.3-21.4) pg/ml in
the placebo group and 12.5 (5.0-24.4) pg/ml in the salmeterol group with no significant
difference between the groups (table 4). The inflammatory mediators measured in
bronchoalveolar lavage fluid (table 3) increased after exposure in both the salmeterol group and
the placebo group with no significant differences between the groups.
Table 4. IL-6 concentrations (pg/ml) in serum from healthy subjects before 2 weeks treatment
with either inhaled placebo (n=8) or salmeterol (50 µg b.i.d.; n=8), one hour before, and 4, 7 and
24 hours after the start of the exposure in a swine barn.
Before -1 hour +4 hours +7 hours + 24 hours
Placebo 1.1
(0.8-1.5)
1.0
(0.8-1.4)
9.1 *
(4.9-11.8)
12.4 *
(6.4-22.6)
1.8
(1.2-3.4)
Salmeterol 1.1
(0.8-2.8)
2.2
(0.9-3.9)
13.2 *
(7.5-30.8)
9.4 *
(7.1-36.5)
2.0
(1.4-3.7)
P<0.05 compared with values obtained one hour before exposure. Differences between the groups
(P=0.6;Mann-Whitney). Median (25th-75th percentiles).
Salmeterol inhalation had no effect on the increased plasma leakage, reflected by increase in
albumin and α2-macroglobulin concentrations in bronchoalveolar lavage fluid, following
exposure (table 3). There are, however, several animal data showing that β2-agonists have the
capacity to reduce extravasation of plasma in animal airways (Tokuyama et al., 1991; Whelan
et al., 1992) but the clinical relevance of this effect in the treatment of asthma is unclear
(Barnes, 2002; Persson, 1993). Greiff et al have found that inhaled formoterol reduced the
increase in plasma proteins in sputum induced by inhaled histamine in normal subjects,
indicating that therapeutic doses of inhaled long acting β2-agonists inhibit plasma exudation
(Greiff et al., 1998). The lack of effect of salmeterol on vascular permeability in our study
might have been influenced by tachyphylaxis.
There are also data reporting mast cell inhibitory effects of β2-agonists (Wallin et al., 1999).
Other findings indicate that β2-agonists may cause reduction in both the number and activation
of neutrophils (Reid et al., 2003). There are also data on inhibitory effects of salmeterol on
allergen induced increases in sputum eosinophils in asthmatic subjects (Dente et al., 1999).
However, the relevance of these effects for the control of airway inflammation in asthma is not
clear (Howarth et al., 2000). We were not able to demonstrate that salmeterol influenced the
marked increase of neutrophils or IL-8 in bronchoalveolar lavage fluid following exposure.
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4.2.2 β2-Agonists: bronchial responsiveness
 (Study V)
 We found that neither two weeks treatment with inhaled salmeterol nor salmeterol inhaled as a
single dose, prior to exposure in a swine barn, altered the increased bronchial responsiveness
to methacholine in healthy subjects. The bronchial responsiveness to methacholine in subjects
receiving salmeterol for two weeks (n=8) increased significantly by 2.6 (1.4 – 3.7) doubling
concentration steps following exposure. This increase did not significantly differ from the
placebo group which increased by 3.2 (2.8-4.1) doubling concentration steps (n=8; figure 5).
The bronchial responsiveness to methacholine in subjects receiving one single dose of
salmeterol (100 µg; n=6) prior to exposure increased by >1.7 (0.4-2.4) doubling concentration
steps and did not significantly differ from subjects receiving placebo (n=6), which increased
by 3.3 (2.9-4.4) doubling concentration steps (figure 5). The explanation to the lack of
bronchoprotective effect of salmeterol against the organic dust-induced increased bronchial
responsiveness is not clear. In healthy non-exposed individuals, bronchial responsiveness to
methacholine was attenuated by 1.2 (0.8-1.7) doubling concentration steps 8 hours after
inhalation of one dose salmeterol (100 µg) compared to inhalation with placebo (figure 6).
 
 
 
 
 Figure 5. Results from Study V. Bronchial responsiveness to methacholine (PC20FEV1) in healthy
subjects, before medication and after exposure in a swine barn, treated either two weeks with
inhaled placebo (n=8) or salmeterol (50 µg b.i.d., n=8; upper panel) or with one dose of placebo
(n=6) or salmeterol (100 µg; n=6; lower panel) Horizontal lines indicate median values and hori-
zontal dashed line represents the highest inhaled concentration of methacholine (64 mg/ml). One
subject did not attain a 20% decrease in FEV1 after exposure when the maximum concentration
was reached, but had a >15% FEV1-decline. No significant difference between the groups. P-values
indicate pre- and post-exposure comparisons and comparisons between the groups.
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 Figure 6. Results from Study V; the PC20FEV1 of eight healthy subjects after inhaling one dose of
placebo or salmeterol (100 µg) 2 hours or 8 hours before the methacholine provocation.
Horizontal lines indicate median values. P-values indicate the PC20FEV1 differences between
salmeterol and placebo inhalations. There were no significant differences between the increase of
PC20FEV1 at 2 or 8 hours.
 
 It is known that regular inhalation of a β2-agonist induces tachyphylaxis and reduction of
the bronchoprotective effect against bronchoconstrictor stimuli. Several studies have
investigated this issue and shown that regular treatment with salmeterol, or other β2-agonists,
induces tolerance to the bronchoprotective effects against methacholine, exercise or allergen
(Bhagat et al., 1995; Cheung et al., 1992; Giannini et al., 1996; January et al., 1998; O'Connor
et al., 1992; Ramage et al., 1994). Additionally, the tolerance to the bronchoprotective effect
of salmeterol against methacholine induced bronchoconstriction occurs rapidly and is found
already 12 hours after starting a twice daily treatment (Drotar et al., 1998). Therefore, it
would be possible that 2 weeks of treatment with salmeterol induced β-adrenoceptor
tachyphylaxis which might, at least in part, explain the reason for the lack of effect of 2 weeks
salmeterol treatment on the increased responsiveness to methacholine induced by exposure in
a swine barn. However, since neither a single dose of salmeterol nor 2 weeks treatment altered
the increased bronchial responsiveness following exposure and since the effect was similar, it
is unlikely that the lack of effect of salmeterol after two weeks of treatment is explained by
development of β2-adrenoceptor tachyphylaxis.
 Our finding that one single dose salmeterol attenuated the bronchial responsiveness in
healthy non-exposed subjects together with the above described results, indicates that
exposure to organic dust has altered the airway response to β2-agonists. One explanation to
this observation may be that pro-inflammatory cytokines released in response to exposure in
the swine house, have direct effects on airway smooth muscle cells that reduce the ability to
relax in response to a β2-agonist. There are an increasing number of studies describing the
mechanism by which IL-1β and TNF-α induce heterologous desensitization of β2-
adrenoceptors leading to decreased responsiveness of the β2-adrenoceptor through a
mechanism involving COX-2 and PGE2 formation (Hakonarson et al., 1996; Koto et al., 1996;
Laporte et al., 2000; Laporte et al., 1998; Moore et al., 2001; Pang et al., 1998; Pang et al.,
1997; Shore, 2002) (figure 7). Pro-inflammatory cytokines (IL-1β and TNF-α) and LPS have
been shown to induce the expression of COX-2 which appears to require the activation of p38
in addition to NF-κB (Steer et al., 2003). COX-2 in turn, increases PGE2 release, resulting in
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increased cAMP formation leading to PKA activation, which results in heterologous
desensitization of the β2-adrenoceptor.
 
 
 
 
 Figure 7. Mechanism of heterologous desensitization of β2-adrenergic receptors. Reprinted from
Respir Physiol Neurobiol, 137, Shore S.A. and Moore P.E., Regulation of beta-adrenergic
responses in airway smooth muscle, 179-195. ©Copyright (2003), with permission from Elsevier.
IL-1β leads to extracellular signal-regulated kinase (ERK) and p38 dependent cyclooxygenase-2
(COX-2) expression and prostaglandin E2 (PGE2) release. PGE2 acts on E prostanoid 2 (EP2)
receptors coupled to stimulatory G  protein (Gs) leading to cyclic AMP (cAMP) formation, and
protein kinase A (PKA) activation. PKA phosphorylates the β2-adrenoceptor, uncoupling it from
Gs (Shore et al., 2003).
 
 Previous studies have reported significantly increased levels of IL-1α and IL-1β in nasal and
bronchoalveolar lavage fluid of healthy subjects after exposure in a swine house (Wang et al.,
1997). Furthermore, concentrations of IL-1β in peripheral blood are also increased after
exposure (Wang et al., 1998). We found elevated TNF-α concentrations in both
bronchoalveolar and nasal lavage fluids following organic dust exposure (table 3). In a previous
study TNF-α levels in serum significantly increased following exposure (Wang et al., 1996).
Therefore, it is not unreasonable to assume that there have been elevated levels of both TNF-α
and IL-1β in the lower airways prior to the methacholine provocation (7 hours after exposure)
and that these cytokines may have influenced the β2-adrenoceptors on airway smooth muscle
cells.
 We found a relation between TNF-α in serum and the increase in bronchial responsiveness
to methacholine after, compared to before, exposure in the subjects who received two weeks
of salmeterol treatment (figure 8). This relationship was not found in the subjects receiving
placebo and has not been shown in previous studies of healthy untreated subjects following
exposure in a swine barn. Additionally, the almost total inhibition of the organic dust-induced
TNF-α release in bronchoalveolar lavage by cromoglycate without influence on bronchial
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responsiveness speaks against a central role of this cytokine in the development of increased
bronchial responsiveness following exposure (Larsson et al., 2001). Thus, TNF-α in serum
does not seem to have influenced bronchial responsiveness itself but might have influenced
effects by the β2-agonist on bronchial responsiveness.
 It could be argued that post-exposure TNF-α levels in serum does not reflect the lower
airway reaction to organic dust exposure. However, we found a relation between increase of
TNF-α in serum (4 and 7 hours after exposure) and bronchoalveolar lavage fluid (24 hours
after exposure) in both groups together (n=16; Rho=0.49; P=0.06 at 4 hours and Rho=0.69;
P=0.008 at 7 hours). In the subjects receiving salmeterol for two weeks there was a
relationship between granulocytes in bronchoalveolar lavage fluid following exposure and the
increase in bronchial responsiveness (n=8; Rho=0.76; P=0.04); this relationship was not found
in the placebo group (n=8; Rho=0.17; P=0.44; figure 8). It is also previously shown that post-
exposure levels of TNF-α in bronchoalveolar lavage fluid was significantly correlated with the
influx of granulocytes into the lower airways (Wang, 1997). Thus, these findings indicate that
TNF-α has influenced the cellular response in the lower airway and this might have influenced
β2-adrenoceptors on airway smooth muscles leading to decreased responsiveness.
 
 
 
 
 Figure 8. Co-variance between the increase in bronchial responsiveness to methacholine
(doubling concentrations steps) following exposure and serum TNF-α concentrations (4 hours
after exposure) and the increase in granulocytes in bronchoalveolar lavage fluid (difference
between pre- and 24 hours post-exposure) in the placebo group (A and C, respectively) and in the
salmeterol group (B and D, respectively).
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4.3 Exposure measurements
Table 5. Concentration of inhalable and respirable dust and endotoxin in the different trials.
Trial Exposure Inhalable
dust
(mg/m3)
Inhalable
endotoxin
(ng/m3)
Respirable
dust
(mg/m3)
Respirable
endotoxin
(ng/m3)
Results in
Study
1 600-900 pigs 25.4
(21.2-34.7)
733
(402-1068)
1.02
(0.76-1.27)
32
(13-56)
III, IV, V
2 300 pigs 11.5
(10.4-18.3)
236
(123-281)
0.68
(0.55-0.93)
41
(28-44)
V
The exposure levels were higher in trial one, probably due to the larger number of pigs in the
swine barn (table 5). There were no significant differences in exposure between the groups in
either trial.
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5.1 Glucocorticoids
 We found that fluticasone treatment attenuated the nasal and systemic inflammatory
responses induced by exposure in a swine barn in vivo. These results were confirmed by our
in vitro data. However, there were no effects of fluticasone treatment on the elevated
inflammatory mediators found in bronchoalveolar lavage fluid or on cytokine release from
alveolar macrophages ex vivo or on the increased bronchial responsiveness following exposure.
There might be several explanations to this discrepancy.
 Our in vitro data demonstrate that glucocorticoids are potent inhibitors of swine house dust
and LPS-induced cytokine release from lung epithelial cells and human alveolar macrophages.
Inhalation of fluticasone or budesonide (one single dose of 1-1.6 mg) has previously been
shown to result in a steroid concentration of approximately 5 nmol/kg in central lung tissue
and the concentration was about 3-4 times lower in peripheral lung tissue in patients who
underwent surgery due to lung cancer (Esmailpour et al., 1997; Van den Bosch et al., 1993). In
healthy subjects with no airway obstruction inhalation of the drug might yield a more
favourable lung deposition. It is not unreasonable to assume that the glucocorticoid
concentration is approximately 1nM in the airway lining fluid during regular inhalation. Since
we found that fluticasone inhibited cytokine release from both lung epithelial cells and alveolar
macrophages significantly at 1 nM, and some cytokines were almost totally inhibited at this
concentration, this effect might be relevant also in vivo.
 However, the concentration of the deposited drug might still not have been enough to elicit
the same effects in the lower airways as we found in vitro. Intra-nasally administered
fluticasone has probably resulted in higher concentrations of the drug in the nasal cavity
compared to the concentrations in peripheral airways following inhalation. Thus, the
difference in glucocorticoid concentration may explain the discrepancy between the findings in
nasal and bronchoalveolar lavage fluids.
 On the other hand, the findings of a lower increase in IL-6 levels in serum in the fluticasone
group and that post-exposure IL-6 levels in nasal lavage fluid was not significantly attenuated
by treatment, indicate that IL-6 concentrations in the airways have been reduced by
fluticasone. Other in vitro studies at our laboratory have shown that swine dust induced
mRNA IL-6 at an early time point and the expression levels of IL-6 reduced with time over a
24 hour period (Burvall et al., 2004). Thus, these findings indicate that the steroid mediated
effect on airway cytokine release is found at an early phase of the inflammatory response to
exposure and that the inflammatory reaction is less intense after 24 hours (at the time of the
bronchoalveolar lavage) in both the placebo and fluticasone group, resulting in less difference
between the groups. This might be an additional explanation for the finding of inhibitory
effects of fluticasone on swine dust-induced IL-6 release in vitro and in serum in vivo but no
effect of fluticasone on IL-6 levels in bronchoalveolar lavage fluid.
 Another explanation for the discrepancy between the in vivo and in vitro results might be
that the cell types from where the cytokines originate differ. Epithelial cells and alveolar
macrophages are important sources of the cytokines and they are most likely the initial
5 General Discussion
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activators of the inflammatory response. However, the inflammatory cells and phagocytic
cells recruited from the peripheral blood into the airways also cause release of cytokines. The
main feature of the inflammatory response to organic dust inhalation was a massive
accumulation of neutrophilic granulocytes in the airways. After exposure there is an 70-75
fold increase in neutrophils, a doubling of alveolar macrophages and the increase in
lymphocytes was about three-fold in bronchoalveolar lavage fluid (Larsson et al., 1994b).
Eosinophils are also significantly increased after exposure in bronchoalveolar lavage fluid,
although the proportion of the total cell concentration is very low (<0.5%) (Larsson et al.,
1994b). Thus, in Study IV, the increase of granulocytes in bronchoalveolar lavage fluid after
exposure consisted mainly of neutrophils (from 3.7% before exposure to 34% of the total cell
count after exposure). In blood there is a three fold increase of granulocytes (Muller-Suur et
al., 1997). These results implicate that neutrophils are important contributors to the cytokine
content and inflammatory response after organic dust inhalation.
 Neutrophils are important sources of pro-inflammatory cytokines, including IL-8 and TNF-
α (Cassatella et al., 1997; Scapini et al., 2000) and glucocorticoids inhibit  IL-8 release from
neutrophils in vitro (Irakam et al., 2002). However, it has also been shown that glucocorticoids
increase neutrophil survival by reducing apoptosis (Haslett, 1999; Meagher et al., 1996; Zhang
et al., 2001). Glucocorticoids exert weak or no inhibitory effect on neutrophilic inflammatory
responses (Cox, 1998; Sampson, 2000) such as the mobilisation of neutrophils in COPD
(Gizycki et al., 2002; Keatings et al., 1997), a condition which is characterized by an increased
number of neutrophils (Lacoste et al., 1993). There is a considerable heterogeneity of the
asthma phenotype and many subjects may exhibit an airway disease characterized by
neutrophilia rather than eosinophilia (Douwes et al., 2002; Gibson et al., 2001). Elevated
levels of neutrophils have been measured in the airways of subjects with acute severe asthma
and during exacerbations (Fahy et al., 1995; Jatakanon et al., 1999; Norzila et al., 2000). There
are data suggesting that glucocorticoids are less effective in attenuating airway inflammation in
asthma patients with high levels of neutrophils (Gauvreau et al., 2002; Inoue et al., 1999).
These data suggest that glucocorticoids may have limited effects on neutrophils and that may
explain the lack of effect of fluticasone on the organic dust-induced neutrophilic influx into the
upper and lower airways (assessed as nasal and bronchoalveolar lavage) in the present study.
Additionally, since neutrophils are not major producers of IL-6, it is possible that the effect of
fluticasone on serum IL-6 levels reflects influences of fluticasone on other airway cells than
neutrophils.
 We found that fluticasone inhibited IL-8 release from LPS-stimulated human alveolar
macrophages in vitro by maximal 33%. Dexamethasone inhibited IL-8 release in stimulated
alveolar macrophages from smokers by maximally 25% and had no effect on IL-8 release in
stimulated alveolar macrophages from patients with COPD (Culpitt et al., 2003). In another
study, dexamethasone suppressed IL-8 release by 64% in non-smokers and by 29% in
smokers (Ito et al., 2001). Thus, there might be a limited effect of glucocorticoids on IL-8
release which might be more pronounced after exposure. This could contribute to the
understanding of the lack of effect of fluticasone on the cytokine and neutrophilic response to
organic dust in the lower airways.
 In previous studies at our laboratory, no relationship between the bronchial responsiveness
to methacholine and the inflammatory response, measured as change in concentration of cells
and mediators (cytokines, leukotrienes and PGD2) following exposure to swine dust, was
found. Sodium cromoglycate significantly reduced the organic dust-induced increase in
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neutrophils, IL-6, TNF-α and myeloperoxidase in bronchoalveolar lavage fluid but did not
affect the increased bronchial responsiveness to methacholine (Larsson et al., 2001).
Administration of zileuton, a leukotriene synthesis inhibitor, also failed to affect the increase
in bronchial responsiveness following exposure in a swine barn (Larsson et al., 2002).
Additionally, wearing respiratory protection device dramatically decreased the inflammatory
cells in blood and mediators in nasal lavage fluid but did only influence the increased bronchial
responsiveness to a minor extent following exposure in a swine barn (Palmberg et al., 2004). It
has been shown that eosinophilic inflammation is associated with increased methacholine
responsiveness (PC20) whereas neutrophilic inflammation is not (Woodruff et al., 2001). The
data suggest that neutrophils might not be involved in the bronchial hyperreactivity observed
in asthma. In most studies, but not in all (Nielsen et al., 2000), glucocorticoid treatment
reduces airway hyperresponsiveness to methacholine in asthmatics (Barnes, 1990; Overbeek
et al., 1996; Reynolds et al., 2002; Van Schoor et al., 2002). We have showed that fluticasone
treatment does not affect the increased bronchial responsiveness to methacholine induced by
organic dust inhalation in healthy subjects. Thus, there does not seem to be a direct
relationship between the neutrophilic inflammation and the increased bronchial responsiveness
to methacholine after exposure in a swine barn.
 NF-κB plays a central role in inflammation and knowledge of its mode of action is
necessary for molecular understanding of inflammatory diseases. It is believed that NF-κB
plays a major role in the onset and maintenance of the asthmatic inflammation. It has been
shown that the levels of pro-inflammatory cytokines, such as IL-1β, TNF-α, IL-6 and IL-8
are elevated in asthmatic airways (Broide et al., 1992; Marini et al., 1992). In addition,
expression of p65, as well as increased NF-κB DNA binding is found in biopsies and induced
sputum from asthmatic subjects (Hart et al., 1998). Our results indicate that acute phase
transcription factors such as NF-κB also may play an important role during the acute
response to organic dust inhalation.
 Several mechanisms by which glucocorticoids act might be important for the inhibition of
swine house dust-induced cytokine release, including repression of NF-κB activity, as shown
in Study II. Understanding of the mode of action of glucocorticoids is of importance in
inhibiting the transcription of inflammatory genes without having negative side effects. It is
believed that anti-inflammatory effects to a major extent are mediated via transrepression,
while many side effects are due to transactivation (Barnes, 1998). This has led to a search for
novel glucocorticoids that are more active in transrepression than transactivation (Schacke et
al., 2004).
 Taken together, glucocorticoids may exert anti-inflammatory effects on the organic dust
induced inflammatory response. The major effects of fluticasone in vivo on the organic dust-
induced inflammatory response are inhibition of cytokine release and plasma leakage into the
nose and attenuation of the fever response and the systemic IL-6 response. These effects
might in part be caused by glucocorticoid-mediated inhibition of pro-inflammatory cytokine
release from epithelial cells and alveolar macrophages. Furthermore, inhibition of NF-κB
activation by fluticasone seems to be a possible mechanism through which pro-inflammatory
cytokines are inhibited. On the other hand, glucocorticoids had no effect on the cell- and
cytokine inflammatory response in the lower airways. This discrepancy might be due to low
glucocorticoid concentration, to methodological time differences or weak inhibitory effects of
glucocorticoids on neutrophilic responses. Additionally, glucocorticoids had no effect on
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bronchial responsiveness and there does not seem to be a direct relation between bronchial
responsiveness and the inflammatory response following exposure in the swine barn.
 
5.2 β2-Agonists
 Although in vitro data indicate that β2-agonists may have anti- (Barnes, 1999) or pro-
inflammatory properties (Kavelaars et al., 1997; Linden, 1996), we did not find any significant
effects of salmeterol treatment on the inflammatory response induced by exposure in a swine
barn. Our results are consistent with a number of studies which suggest that salmeterol has no
or small effects on airway inflammation in asthma (Howarth et al., 2000; Li et al., 1999;
Lindqvist et al., 2003; Roberts et al., 1999). Bronchoalveolar lavage studies have not shown
any significant influence of salmeterol on airway inflammatory cells in patients with stable
asthma (Gardiner et al., 1994; Kraft et al., 1997). Thus, there are still no clear data to support
that salmeterol exerts any clinically significant anti-inflammatory effects in man.
 Many different factors have been suggested to be involved in airway hyperresponsiveness.
Separate mechanisms are probably responsible for the underlying hyperresponsiveness in
asthmatic patients and in normal individuals (Lotvall et al., 1998; O'Byrne & Inman, 2000).
However, the mechanism of the increased bronchial responsiveness in healthy subjects
following exposure in a swine barn might have similarities with the transient worsening of
asthma control. It is known that β2-agonists fail to relieve symptoms in patients during acute
asthma exacerbations induced by airway infections (Rebuck et al., 1971; Reddel et al., 1999).
Respiratory tract infection is a common cause of acute asthma exacerbations in children and
adults. In most of these episodes the infection is caused by respiratory viruses but bacterial
pathogens are also recognized as causative agents (Lieberman et al., 2003). Airway
neutrophilia and increased levels of pro-inflammatory cytokines such as IL-1, IL-8 and TNF-
α are associated with both bacterial and viral inflammation causing exacerbations of asthma
(Gern, 2004; Mizgerd, 2002). The mechanism behind this impaired β2-adrenoceptor function
might thus be similar to what we have found following exposure to organic dust. In agreement
with the previous discussion (5.2.2), the pro-inflammatory cytokines IL-1β and TNF-α might
have a role in the pathogenesis of attenuated β-adrenoceptor-responses.
 
5.3 Future perspectives
Current evidence suggest that the combination of inhaled corticosteroids and long acting β2-
agonists is the most effective means of controlling asthma and used in combination they are
more effective than either drug alone. There might thus be additive or synergistic benefits of
the combination of glucocorticoids together with β2-agonists. Although glucocorticoids have a
number of actions in the inflamed airway, an additional important way in which
glucocorticoids may be effective in asthma is through direct effects on smooth muscle through
inhibition of cytokine-induced hyporesponsiveness to β2-agonists (Adcock et al., 2002;
Moore et al., 1999). Furthermore, combining  a β2-agonist with a COX-2 inhibitor might more
directly inhibit this mechanism. Thus, further studies using the acute inflammatory response
following swine house dust exposure as a model, may increase the understanding of the
inflammatory response and provide new targets for pharmacological intervention when
treating chronic airways inflammation.
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• Glucocorticoids are potent inhibitors of swine house dust-induced cytokine release
from lung epithelial cells (IL-6 and IL-8) and of LPS-induced cytokine release (IL-6,
IL-8 and TNF-α) from human alveolar macrophages in vitro at concentrations likely to
be found in the airways during inhalation therapy. The onset of the cytokine
suppression by glucocorticoids in vitro was rapid and might thus be a direct, non-gene
mediated, effect.
 
• Swine house dust stimulation of lung epithelial cells activated the transcription factor
NF-κB, involved in mediating the release of IL-6 and IL-8. The mechanisms by which
glucocorticoids suppress swine house dust-induced cytokine release from epithelial
cells in vitro include repression of NF-κB activity.
 
• Fluticasone attenuated the inflammatory response in the upper airways, attenuated the
fever response and attenuated the systemic IL-6 response induced in healthy subjects
following exposure in a swine barn. However, fluticasone did not affect the cell- and
cytokine inflammatory response in the lower airways. This discrepancy might be due
to differences in steroid concentration, to methodological time differences or that
glucocorticoids have only weak or no inhibitory effects on neutrophilic responses.
 
• Inhalation of fluticasone attenuated the IL-6 serum response and the increase in body
temperature following exposure in a swine barn. There might be a causal relationship
between glucocorticoid-induced attenuation of serum IL-6 and body temperature
increases.
 
• Intra-nasal administered fluticasone attenuated plasma leakage, assessed as albumin
concentrations, and attenuated the IL-8 and TNF-α  concentrations in nasal lavage
fluid following exposure in a swine barn. The inhibition of plasma leakage by
glucocorticoids might reflect the ability of the drug to inhibit inflammatory mediators
such as IL-8 and LTE4, which have been shown to influence vascular leakage.
 
• Fluticasone inhalation had no effect on the increased bronchial responsiveness to
methacholine following exposure. There might be no direct relationship between the
inflammation and the increased bronchial responsiveness in healthy subjects following
exposure in a swine barn.
 
• Exposure of healthy individuals in a swine barn reduced the capability of alveolar
macrophages to release cytokines ex vivo indicating that alveolar macrophages have a
reduced function after exposure. Pre-exposure treatment with either salmeterol or
fluticasone did not influence this capability.
 
6 Conclusions
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• Salmeterol inhalation had no effect on the inflammatory responses to inhaled organic
dust supporting the theory that salmeterol has no or little influence on airway
inflammation in human.
 
• Salmeterol inhalation did not alter the increased responsiveness to methacholine
following exposure, neither when inhaled regularly during 2 weeks prior to exposure
nor when administered as a single dose prior to exposure. However, salmeterol caused
a decreased responsiveness to methacholine in healthy unexposed subjects 2 and 8
hours after inhalation. This indicates that the lack of protective effect of salmeterol
was not due to homologous β2-adrenoceptor desensitization but rather that exposure
to organic material may have altered the airway response to β2-agonists. Our
hypothesis is that pro-inflammatory cytokines, such as IL-1β and TNF-α, have
influenced β2-adrenoceptors on airway smooth muscles leading to decreased β2-
adrenergic responses.
35
Exposure of healthy subjects in a swine barn causes an acute inflammatory response in the
airways and an increase in bronchial responsiveness to methacholine. The aim of this thesis
was to study the mechanisms by which glucocorticoids or β2-agonists interfere with the
inflammatory response following swine house dust-exposure both in vitro and in vivo.
In the first study, the effect of fluticasone or budesonide on cytokine response in swine
house dust-stimulated A549 lung epithelial cells (IL-6 and IL-8) and in LPS-stimulated human
alveolar macrophages (IL-6, IL-8 and TNF-α) was evaluated. The glucocorticoids caused a
dose-response inhibition of the cytokines and potent effects were found at concentrations that
are likely to be found in the airways during inhalation therapy. Furthermore, the onset of the
cytokine suppression by glucocorticoids in vitro was rapid.
In the second study, the involvement of NF-κB on swine house dust-mediated IL-6 and IL-
8 release from A549 lung epithelial cells and the influence of glucocorticoids was evaluated. By
interfering with the NF-κB pathway at different levels, it was demonstrated that swine dust
stimulation activated NF-κB and cytokine release. In addition, it was shown that the
glucocorticoid-mediated cytokine inhibition might, in part, be explained by inhibition of NF-
κB activation.
In the third study, the effect of treatment with fluticasone (inhalation and intra-nasally) on
the upper airway inflammatory response, the systemic response and the increased bronchial
responsiveness to methacholine induced in healthy subjects following exposure in a swine
barn, was evaluated.  Intranasal fluticasone attenuated plasma leakage, assessed as albumin
concentrations, and cytokine concentrations in nasal lavage fluid (IL-8 and TNF-α).
Fluticasone treatment also attenuated serum IL-6 levels and body temperature increases but
not the increased bronchial responsiveness following exposure.
In the fourth study, the effect of inhaled fluticasone or salmeterol on the lower airway
inflammatory response induced in healthy individuals following exposure in a swine barn was
evaluated. There were no effects of fluticasone or salmeterol treatment on the increase in cell
concentration and cytokine release in bronchoalveolar lavage fluid following exposure.
Additionally, exposure reduced the capability of alveolar macrophages to release cytokines ex
vivo and pre-exposure treatment did not affect this capability.
Last, the effect of the long-acting β2-agonist salmeterol, on the increased bronchial
responsiveness to methacholine, induced in healthy subjects exposed in a swine barn, was
investigated. Salmeterol inhalation did not alter the increased responsiveness to methacholine
following exposure, neither when inhaled regularly during 2 weeks prior to exposure nor when
administered as a single dose prior to exposure. However, salmeterol inhalation caused a
decreased responsiveness in healthy unexposed subjects. This indicates that the lack of
protective effect of salmeterol was not due to homologous β2-adrenoceptor desensitization but
rather that exposure may have altered the airway response to β2-agonists.
In conclusion, glucocorticoids may exert anti-inflammatory effects on the organic dust
induced inflammatory response. Glucocorticoid-mediated inhibition of pro-inflammatory
cytokines, through inhibition of NF-κB activation, might be an important mechanism by
which these effects are exerted. On the other hand, the glucocorticoid had no effect on the
7 Summary
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inflammatory response in the lower airways or on the increased bronchial responsiveness
following exposure. Salmeterol did neither influence the inflammatory response nor the
increased bronchial responsiveness following exposure.
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Friska, tidigare oexponerade individer som exponeras tre timmar i svinhusmiljö får kraftig
inflammation i både övre och nedre luftvägar samt en ökad bronkiell reaktivitet mot metakolin.
Syftet med denna avhandling var att studera effekten av glukokortikoider och β2-agonister på
denna akuta inflammatoriska reaktion både in vitro och in vivo.
I det första delarbetet studerades dos-respons effekten av flutikason propionate eller
budesonid och tidskinetiken på cytokinfrisättningen från svinhusdamms-stimulerade A549
lungepitelceller (IL-6 och IL-8) och LPS-stimulerade humana alveolära makrofager (IL-6, IL-8
och TNFα). Glukokortikoiderna hämmade cytokinerna i ett dos-respons förhållande och en
kraftig hämning påvisades vid koncentrationer som mycket väl kan uppnås i luftvägarna vid
normal dosering av inhalationssteroid. Tidsstudierna tyder på att verkningsmekanismen är
snabb.
I det andra delarbetet undersöktes om NF-κB är involverad vid svinhusdamms-inducerad
cytokinfrisättning från A549 lungepitelceller och om glukokortikoider interagerar med denna
transkriptionsfaktorn. Genom att hämma eller inaktivera NF-κB på olika sätt visades att
svinhusdamm aktiverade NF-κB, som var involverad i IL-6 och IL-8 frisättningen. Resultaten
visade också att glukokortikoiders hämning av cytokinfrisättning dels verkar genom interaktion
med NF-κB.
I det tredje delarbetet studerades effekten av flutikason propionate (inhalerat och
intranasalt) på den inflammatoriska responsen i övre luftvägar, den systemiska reaktionen och
på den ökade bronkiella metakolinreaktiviteten som inducerats hos friska individer efter
exponering i svinhus. Flutikason hämmade plasma läckage, mätt som albumin- och α2-
makroglobulin-koncentrationer, och ökningen av cytokinkoncentrationer i nasalsköljvätska
efter exponering. Dessutom hämmades ökningen av IL-6 koncentrationer i serum och ökningen
av kroppstemperaturen efter exponering, av behandlingen.  Däremot hade flutikason ingen
effekt på ökningen av bronkiell reaktivitet. Slutsatsen var att glukokortikoider dämpar
inflammationen i övre luftvägar och påverkar den systemiska reaktionen som inducerats av
exponering i svinhus utan att påverka ökningen av bronkiell reaktivitet.
I det fjärde delarbetet studerades hur salmeterol eller flutikason behandling påverkar de
nedre luftvägarna och makrofagernas förmåga att frisätta cytokiner ex vivo efter exponering i
svinhus. Varken flutikason eller salmeterol påverkade den kraftiga cell- och cytokin-
koncentrationsökningen i nedre luftvägarna efter exponering. Exponeringen ledde till en
reducering av den basala cytokinfrisättningen (IL-6, IL-8 och TNF-α) från alveolära
makrofager ex vivo och denna påverkades inte av behandling.
I det sista delarbetet, undersöktes effekten av den långverkande β2-agonisten salmeterol, på
den ökade bronkiella reaktiviteten mot metakolin inducerad hos friska personer efter
exponering i svinhusmiljö. Varken två veckors behandling eller en enda dos påverkade den
ökade bronkiella reaktiviteten efter exponering. Hos oexponerade friska individer minskade
däremot bronkiell reaktivitet mot metakolin efter inhalation av salmeterol. Resultaten indikerar
att den uteblivna skyddande effekten av salmeterol efter exponering inte beror på homolog
8 Sammanfattning
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desensitisering av β2-adrenoceptorn utan att exponering för organiskt damm kan ha lett till en
förändrad luftvägsrespons mot β2-agonister.
Sammanfattningsvis visades att glukokortikoider har anti-inflammatoriska effekter på den
inflammatoriska reaktionen som inducerats hos friska individer av exponering i svinstall.
Glukokortikoid-medierad hämning av pro-inflammatoriska cytokiner, via hämning av NF-κB
aktivering, kan vara en betydelsefull mekanism för dessa effekter. Däremot hade
glukokortikoider ingen effekt på den nedre luftvägsinflammationen vilket kan bero på
skillnader i steroidkoncentration, metodologiska tidsskillnader eller på att glukokortikoider inte
påverkar neutrofila inflammatoriska förlopp. Dessutom påverkade glukokortikoiden inte
bronkiell reaktivitet och det verkar inte finnas något direkt samband mellan bronkiell reaktivitet
och den inflammatoriska reaktionen som inducerats hos friska individer efter exponering i
svinhus. β2-Agonisten salmeterol påverkade inte den inflammatoriska reaktionen, mätt som
cell-, cytokin- och plasmaproteinkoncentrationer i bronkoalveolärsköljvätska eller serum, efter
svinhusexponering.  Resultaten angående den uteblivna skyddande effekten av salmeterol på
den ökade bronkiella metakolinreaktiviteten efter exponering indikerar att exponeringen har
förändrat β2-receptorfunktionen och att pro-inflammatoriska cytokiner kan spela en roll vid
denna mekanism.
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